Tag : R/R FLT3mut+ AML

CONFERENCE UPDATE

Post-HSCT gilteritinib resumption improves OS in R/R FLT3mut+ AML: Pooled analysis of the phase 3 ADMIRAL and COMMODORE trials
Gilteritinib resumption post-hematopoietic stem cell transplantation (HSCT) improved overall survival (OS) in relapsed/refractory FMS-like tyrosine kinase 3-mutated acute myeloid leukemia (R/R FLT3mut+ AML) in a pooled analysis of ADMIRAL and COMMODORE, with landmark data suggesting reduced relapse or death in relapse-free day-60 HSCT patients.